However, it has been shown that mutations in NFE2L2 occur in the early stages of HCC, and whilst the prevalence of NFE2L2 mutations decreases as the disease increases in severity, NRF2 activity remains heightened throughout HCC progression [252]. This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.